![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 23, 2023 3:41:53 PM
And.... over that period of time standard of care (SOC) continued to improve. So biotech therapies during their FDA studies were constantly competing against improving SOC. IMO it was improving SOC is what took the legs out of most biotech FDA covid studies. As far as I could tell, most FDA studies for covid did not 100% decouple their primary endpoints from SOC. Investors who made a lot of $$ on the covid biotech sector did so by selling 'on the hype'. Those that lost $$ typically were those that held their shares down to the end (FDA trial completions).
Now RVVTF must dump/dilute more shares to keep paying their high compensation packages. The O/S and float will continue to grow. I now only see one undesirable outcome for this when MF and other officers realize that they need to re-energize this cash cow machine while they continue to pursue the DREAM of actually generating sales from a real product. Shroom sales just won't cut it IMO.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM